title: [Effect of combination chemotherapy with cis-dichlorodiammineplatinum on relapsed or therapy-resistant non-Hodgkin's lymphoma].
authors.forename: K
authors.initials: K
authors.lastname: Tsukasaki
authors.forename: S
authors.initials: S
authors.lastname: Ikeda
authors.forename: S
authors.initials: S
authors.lastname: Momita
authors.forename: K
authors.initials: K
authors.lastname: Nagai
authors.forename: K
authors.initials: K
authors.lastname: Murata
authors.forename: S
authors.initials: S
authors.lastname: Tokunaga
authors.forename: T
authors.initials: T
authors.lastname: Kohno
authors.forename: T
authors.initials: T
authors.lastname: Itoyama
authors.forename: K
authors.initials: K
authors.lastname: Toriya
authors.forename: K
authors.initials: K
authors.lastname: Kuriyama
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D002945:Cisplatin